Gen Digital Inc.
GEN is priced like a no-growth legacy security asset at 12.66x P/E, while management has already raised FY27 to 8%-10% revenue growth and $2.85-$2.95 EPS, with synergies and partner-led distribution extending the earnings curve.
GEN is trading as if it is still a slow-growth, ex-growth cybersecurity roll-up, but the latest operating evidence says the earnings base is improving faster than the share price reflects. FY2026 revenue grew only 2.0% to $5.0B, which explains some skepticism, yet the latest quarter changed the slope: Q4 revenue reached $1.28B, beat the high end of guidance, and management raised FY27 to $5.325B-$5.425B of revenue and $2.85-$2.95 of non-GAAP EPS. That is not a subtle change. It implies a meaningful acceleration in growth and a much stronger earnings year ahead than the trailing $1.59 EPS figure suggests.
The market is also underpricing how much of GEN's growth is now coming from newer engines rather than the legacy Norton-style narrative. Trust-Based Solutions grew 20% pro forma, MoneyLion delivered 40%+ growth, and Engine approached a $1B run rate. Management also said, "With this momentum growing, we see over $100 million in incremental annual revenue from embedded financial wellness partner expansion and engine growth beginning in the second half of fiscal year '27 and scaling into '28 and '29." That matters because it makes the FY27 acceleration look supported by identifiable programs, not just a hope for macro recovery.
The valuation remains the clearest part of the case. At 12.66x P/E and 2.6x P/S, GEN trades well below peer averages of 21.3x and 6.5x, even though it still posts elite margins, including a 40.9% FY2026 operating margin and 51.6% Q4 EBITDA margin. The stock is also 30.4% below its 52-week high and 10.7% below its 200-day average, so this is not a momentum-chasing setup. If GEN simply proves that FY27 guidance is durable, the multiple does not need to reach premium software levels for the stock to work.
What keeps conviction at Medium rather than High is simple: leverage. $8.2B of debt, 5.70x Debt/EBITDA, and a 0.47 current ratio leave little room for a stumble. AI is a real opportunity through distribution and product relevance, but management has already warned that FY27 AI revenue will be modest and lower margin. The case depends on three things: delivering the raised FY27 guide, converting >$100M of revenue synergies starting in 2H FY27, and continuing debt reduction fast enough that the market can underwrite the earnings stream with less balance-sheet discount.
Quant call (BUY) diverges from analyst consensus (Hold: 0 buy / 3 hold / 0 sell) — resolve explicitly.
The single greatest edge an investor can have is a long-term orientation.
FY27 is the inflection year the market is not fully crediting. Using management's $2.85-$2.95 non-GAAP EPS guide, the stock is trading at roughly a high-single-digit forward earnings multiple, far below the 12.66x trailing P/E and still below peers even after allowing for GEN's debt burden. The moat is shifting from a mature consumer cyber bundle toward a broader trust, identity, and embedded financial wellness platform, supported by 30+ new partnerships in Q4 and distribution wins including Microsoft Copilot/MSN AI and Equifax. AI is a mixed force, it should expand distribution and workflow relevance, but management has already flagged that FY27 AI revenue is modest and lower margin, so the 3-5 year upside depends more on partner-led scale and cross-sell than on near-term AI monetization alone.
- FY27 guidance implies a step-up from 2.0% FY2026 revenue growth to 8%-10% pro forma growth, with revenue guided to $5.325B-$5.425B.
- Forward earnings power is materially above trailing results, with FY27 non-GAAP EPS guided to $2.85-$2.95 versus $1.59 FY2026 EPS.
- The stock trades at 12.66x P/E and 2.6x P/S, both well below peer averages of 21.3x and 6.5x, while price is -30.4% versus the 52-week high.
- Management raised FY27 outlook after Q4 revenue of $1.28B exceeded the high end of guidance, and guided to 8%-10% pro forma growth after FY2026 delivered only 2.0% growth.
- Earnings execution has been steady, with 8 straight EPS beats, including $0.71 vs $0.689 on 2026-08-06 and $0.67 vs $0.65 on 2026-05-07.
- Profitability is real, not promotional: FY2026 operating margin was 40.9%, and Q4 EBITDA margin reached 51.6%, up about 540 bps from Q1.
- New growth legs are becoming tangible, with Trust-Based Solutions up 20% pro forma, MoneyLion at 40%+ growth, Engine near a $1B run rate, and management calling for >$100M incremental annual revenue starting in 2H FY27.
- Leverage is still the biggest blemish, with Debt/EBITDA 5.70, Debt/Equity 3.08, $8.2B of debt, and a weak 0.47 current ratio.
- Free cash flow is positive but not yet robust against the debt load, at only $0.4B in FY2026 versus $8.2B of total debt.
- AI monetization is early and lower quality than the core business, with management saying agentic AI revenue will be modest in FY27 and that AI-related offerings carry lower profit margin than core cyber safety memberships.
- The stock may stay volatile near term, with price action at -29.01% in 1 month, -16.05% in 1 week, and short interest at 6.55%, which suggests the market still doubts durability of the growth re-acceleration.
| Metric | Value | Context |
|---|---|---|
| Current price | $22.02 | Reference price for the $38.25 target, implying 73.7% upside |
| Quant price target | $38.25 | Medium confidence, basis earnings_growth_blend |
| FY2026 revenue | $5.0B | 2.0% YoY growth, modest trailing base before FY27 acceleration |
| FY2026 EPS | $1.59 | 6.1% YoY growth |
| FY2026 operating margin | 40.9% | Flat versus prior FY, shows margin resilience despite low growth |
| FY27 guidance | $5.325B-$5.425B revenue | 8%-10% pro forma growth after Q4 raise |
| FY27 EPS guidance | $2.85-$2.95 | Management called for 13%-17% pro forma EPS growth, 15% at midpoint |
| Valuation | 12.66x P/E | 2.6x P/S | Below peer averages of 21.3x P/E and 6.5x P/S |
| Leverage | 5.70x Debt/EBITDA | 3.08 Debt/Equity | Main reason conviction is not higher |
| Liquidity and debt | 0.47 current ratio | $8.2B total debt | Balance sheet remains the core risk |
| Free cash flow | $0.4B | Positive, but light relative to debt load |
| 52-week position | $17.78-$31.65 range | Current price is -30.4% vs high and -10.7% below 200-day average |
The biggest risk is that leverage limits equity upside if growth slips, because GEN carries Debt/EBITDA of 5.70 and only $0.4B of FY2026 free cash flow against $8.2B of debt.
The next catalyst is the November 5, 2026 earnings report, especially whether Q1 FY27 lands within the guided $1.30B-$1.325B revenue and $0.68-$0.70 EPS range and whether management reinforces the >$100M 2H FY27 synergy ramp.
GEN posted a strong Q4 and raised FY27 growth outlook.
So for fiscal year '27, we are raising our outlook to 8% to 10% revenue growth and mid-teens EPS growth, driven by the progress I've just outlined, including revenue synergies and AI-led efficiencies.
We expect full year revenue in the range of $5.325 billion to $5.425 billion, translating to 8% to 10% pro forma growth.
We expect non-GAAP EPS to be in the range of $2.85 to $2.95, which reflects mid-teens pro forma growth of 13% to 17% with 15% at the midpoint.
We delivered another exceptional quarter, exceeding the high end of our guidance, driven by record bookings and revenue, mid-teens EPS growth and robust free cash flow.
With this momentum growing, we see over $100 million in incremental annual revenue from embedded financial wellness partner expansion and engine growth beginning in the second half of fiscal year '27 and scaling into '28 and '29.
GEN is a BUY because the stock price still reflects the old company while the income statement is starting to reflect the new one. The setup is attractive: a beaten-down share price, a low 12.66x earnings multiple, raised FY27 guidance to $2.85-$2.95 EPS, and visible partner-led growth vectors. The balance sheet is the reason conviction stays Medium, not the operating trajectory. A downgrade case would require evidence that FY27 growth is slipping or that deleveraging stalls, especially given 5.70x Debt/EBITDA. If management keeps executing to guide, the stock has room to close a meaningful part of the gap toward the $38.25 target.
≣ Full research note tap to expand
Executive Summary
BUY, Medium conviction. GEN rates a BUY at Medium conviction. The stock sits 30.4% below its 52-week high after a sharp drawdown, yet the business just posted a strong Q4, lifted FY27 guidance to $5.325B-$5.425B revenue and $2.85-$2.95 non-GAAP EPS, and is trading at 12.66x earnings versus a 21.3x peer average. The case is not balance-sheet-clean, debt remains the key constraint, but the market is discounting an earnings base that is moving materially higher.
Investment Thesis
GEN is trading as if it is still a slow-growth, ex-growth cybersecurity roll-up, but the latest operating evidence says the earnings base is improving faster than the share price reflects. FY2026 revenue grew only 2.0% to $5.0B, which explains some skepticism, yet the latest quarter changed the slope: Q4 revenue reached $1.28B, beat the high end of guidance, and management raised FY27 to $5.325B-$5.425B of revenue and $2.85-$2.95 of non-GAAP EPS. That is not a subtle change. It implies a meaningful acceleration in growth and a much stronger earnings year ahead than the trailing $1.59 EPS figure suggests.
The market is also underpricing how much of GEN's growth is now coming from newer engines rather than the legacy Norton-style narrative. Trust-Based Solutions grew 20% pro forma, MoneyLion delivered 40%+ growth, and Engine approached a $1B run rate. Management also said, "With this momentum growing, we see over $100 million in incremental annual revenue from embedded financial wellness partner expansion and engine growth beginning in the second half of fiscal year '27 and scaling into '28 and '29." That matters because it makes the FY27 acceleration look supported by identifiable programs, not just a hope for macro recovery.
The valuation remains the clearest part of the case. At 12.66x P/E and 2.6x P/S, GEN trades well below peer averages of 21.3x and 6.5x, even though it still posts elite margins, including a 40.9% FY2026 operating margin and 51.6% Q4 EBITDA margin. The stock is also 30.4% below its 52-week high and 10.7% below its 200-day average, so this is not a momentum-chasing setup. If GEN simply proves that FY27 guidance is durable, the multiple does not need to reach premium software levels for the stock to work.
What keeps conviction at Medium rather than High is simple: leverage. $8.2B of debt, 5.70x Debt/EBITDA, and a 0.47 current ratio leave little room for a stumble. AI is a real opportunity through distribution and product relevance, but management has already warned that FY27 AI revenue will be modest and lower margin. The case depends on three things: delivering the raised FY27 guide, converting >$100M of revenue synergies starting in 2H FY27, and continuing debt reduction fast enough that the market can underwrite the earnings stream with less balance-sheet discount.
Key Metrics
| Metric | Value | Context | |
|---|---|---|---|
| Current price | $22.02 | Reference price for the $38.25 target, implying 73.7% upside | |
| Quant price target | $38.25 | Medium confidence, basis earnings_growth_blend | |
| FY2026 revenue | $5.0B | 2.0% YoY growth, modest trailing base before FY27 acceleration | |
| FY2026 EPS | $1.59 | 6.1% YoY growth | |
| FY2026 operating margin | 40.9% | Flat versus prior FY, shows margin resilience despite low growth | |
| FY27 guidance | $5.325B-$5.425B revenue | 8%-10% pro forma growth after Q4 raise | |
| FY27 EPS guidance | $2.85-$2.95 | Management called for 13%-17% pro forma EPS growth, 15% at midpoint | |
| Valuation | 12.66x P/E | 2.6x P/S | Below peer averages of 21.3x P/E and 6.5x P/S |
| Leverage | 5.70x Debt/EBITDA | 3.08 Debt/Equity | Main reason conviction is not higher |
| Liquidity and debt | 0.47 current ratio | $8.2B total debt | Balance sheet remains the core risk |
| Free cash flow | $0.4B | Positive, but light relative to debt load | |
| 52-week position | $17.78-$31.65 range | Current price is -30.4% vs high and -10.7% below 200-day average |
Financial Strength
GEN's P&L is stronger than its balance sheet. A 40.9% operating margin, 16.3% net margin, and 51.6% Q4 EBITDA margin show a business with real earnings power and disciplined costs. The issue is capital structure: 5.70x Debt/EBITDA, 3.08 debt/equity, $8.2B of debt, and a 0.47 current ratio mean equity holders are still underwriting a leveraged story, not a clean compounder. Management's note that net leverage reached 3x a year ahead of plan is encouraging, but with FY2026 free cash flow at only $0.4B, further deleveraging must continue for the market to pay a meaningfully higher multiple.
Competitive Position
GEN still has a durable installed base and brand in consumer cyber safety, but the more important competitive question is whether it can widen that moat into identity, trust, shopping, and financial wellness before commoditization bites. The evidence is improving: Trust-Based Solutions grew 20% pro forma, MoneyLion grew 40%+, and Engine signed 30+ new partnerships in Q4, including distribution through Microsoft Copilot/MSN AI and Equifax. That partner network is the moat extension, because it embeds GEN closer to customer workflows and acquisition channels rather than relying only on direct subscription renewals. The weak spot is innovation intensity, with an Innovation Investment sub-score of 33, so moat durability over 3-5 years depends on execution in these partnerships more than on pure product leadership.
Management & Guidance
Management has earned a fair amount of credibility. GEN has delivered 8 straight EPS beats, though most were modest, ranging from +0.2% to +6.7%, and the latest quarter again exceeded guidance on both revenue and EPS. The tone of the FY27 raise was backed by specifics, not just optimism: "So for fiscal year '27, we are raising our outlook to 8% to 10% revenue growth and mid-teens EPS growth, driven by the progress I've just outlined, including revenue synergies and AI-led efficiencies." That said, management was also appropriately sober on AI, acknowledging FY27 agentic AI revenue will be modest and lower margin. The guidance looks credible because it is supported by bookings, partner expansion, and identified synergies, but investors should demand proof by the November report and the 2H FY27 revenue synergy cadence.
Bull Case
- Management raised FY27 outlook after Q4 revenue of $1.28B exceeded the high end of guidance, and guided to 8%-10% pro forma growth after FY2026 delivered only 2.0% growth.
- Earnings execution has been steady, with 8 straight EPS beats, including $0.71 vs $0.689 on 2026-08-06 and $0.67 vs $0.65 on 2026-05-07.
- Profitability is real, not promotional: FY2026 operating margin was 40.9%, and Q4 EBITDA margin reached 51.6%, up about 540 bps from Q1.
- New growth legs are becoming tangible, with Trust-Based Solutions up 20% pro forma, MoneyLion at 40%+ growth, Engine near a $1B run rate, and management calling for >$100M incremental annual revenue starting in 2H FY27.
Bear Case
- Leverage is still the biggest blemish, with Debt/EBITDA 5.70, Debt/Equity 3.08, $8.2B of debt, and a weak 0.47 current ratio.
- Free cash flow is positive but not yet robust against the debt load, at only $0.4B in FY2026 versus $8.2B of total debt.
- AI monetization is early and lower quality than the core business, with management saying agentic AI revenue will be modest in FY27 and that AI-related offerings carry lower profit margin than core cyber safety memberships.
- The stock may stay volatile near term, with price action at -29.01% in 1 month, -16.05% in 1 week, and short interest at 6.55%, which suggests the market still doubts durability of the growth re-acceleration.
Valuation & Price Target
Engine price target $38.25 (+73.7% vs current), Medium confidence.
- P/E Multiple: $38.19 (28% weight)
- P/S Multiple: $54.3 (9% weight)
- Quality-adjusted: $25.87 (20% weight)
- DCF: $118.95 (1% weight)
The rating stays aligned with the quant baseline BUY, but with only Medium conviction because the valuation gap is clear while the balance sheet is not. The quant target is $38.25, based on an earnings-growth blend, and that logic fits the setup better than sales-based or DCF outputs given the company's 12.66x P/E, raised FY27 EPS guide of $2.85-$2.95, and consistent beat record. Confidence is capped because peer P/E dispersion is wide at 4.9x, leverage is elevated at 5.70x Debt/EBITDA, and analyst consensus is only Hold from 3 firms, which is useful context but too thin to outweigh the numbers.
Risk Assessment
Risk score 42/100 (Moderate). The biggest risk is that leverage limits equity upside if growth slips, because GEN carries Debt/EBITDA of 5.70 and only $0.4B of FY2026 free cash flow against $8.2B of debt.
The Bottom Line
GEN is a BUY because the stock price still reflects the old company while the income statement is starting to reflect the new one. The setup is attractive: a beaten-down share price, a low 12.66x earnings multiple, raised FY27 guidance to $2.85-$2.95 EPS, and visible partner-led growth vectors. The balance sheet is the reason conviction stays Medium, not the operating trajectory. A downgrade case would require evidence that FY27 growth is slipping or that deleveraging stalls, especially given 5.70x Debt/EBITDA. If management keeps executing to guide, the stock has room to close a meaningful part of the gap toward the $38.25 target.
Go deeper in the app
Live charts, options analytics, the full earnings-call breakdown, price alerts, and every other stock — updated in real time.
Get Tickr